tirzepatide for weight loss approval is FDA-approved management, with clinical trials showing average weight of 15–22.5% over 72 weeks. It's a prescription-only therapy, meaning it's not for everyone, and it works by acting Semaglutide and Tirzepatide are FDA-approved

Hormonal normalisation and libido recovery typically take several weeks to months following restoration of adequate energy intake

The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP -1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP -1 receptor agonists

Originally developed to treat type 2 diabetes, it has shown promise in helping individuals lose weight

Forest plot of GLP-1 receptor agonists versus comparators on the risk of Pleural effusion

Implement structured taper

Hypothyroidism can develop with long-term HGH use as the hormone suppresses thyroid function